OBJECTIVE: HIV-positive pregnant women are at heightened risk of becoming lost to follow-up (LTFU) from HIV care. We examined LTFU before and after delivery among pregnant women newly diagnosed with HIV. METHODS: Observational cohort study of all pregnant women ≥18 years (N = 300) testing HIV positive for the first time at their first ANC visit between January and June 2010, at a primary healthcare clinic in Johannesburg, South Africa. Women (n = 27) whose delivery date could not be determined were excluded. RESULTS: Median (IQR) gestation at HIV testing was 26 weeks (21-30). Ninety-eight per cent received AZT prophylaxis, usually started at the first ANC visit. Of 139 (51.3%) patients who were ART eligible, 66.9% (95% CI 58.8-74.3%) initiated ART prior to delivery; median (IQR) ART duration pre-delivery was 9.5 weeks (5.1-14.2). Among ART-eligible patients, 40.5% (32.3-49.0%) were cumulatively retained through 6 months on ART. Of those ART-ineligible patients at HIV testing, only 22.6% (95% CI 15.9-30.6%) completed CD4 staging and returned for a repeat CD4 test after delivery. LTFU (≥1 month late for last scheduled visit) before delivery was 20.5% (95% CI 16.0-25.6%) and, among those still in care, 47.9% (95% CI 41.2-54.6%) within 6 months after delivery. Overall, 57.5% (95% CI 51.6-63.3%) were lost between HIV testing and 6 months post-delivery. CONCLUSIONS: Our findings highlight the challenge of continuity of care among HIV-positive pregnant women attending antenatal services, particularly those ineligible for ART.
OBJECTIVE: HIV-positive pregnant women are at heightened risk of becoming lost to follow-up (LTFU) from HIV care. We examined LTFU before and after delivery among pregnant women newly diagnosed with HIV. METHODS: Observational cohort study of all pregnant women ≥18 years (N = 300) testing HIV positive for the first time at their first ANC visit between January and June 2010, at a primary healthcare clinic in Johannesburg, South Africa. Women (n = 27) whose delivery date could not be determined were excluded. RESULTS: Median (IQR) gestation at HIV testing was 26 weeks (21-30). Ninety-eight per cent received AZT prophylaxis, usually started at the first ANC visit. Of 139 (51.3%) patients who were ART eligible, 66.9% (95% CI 58.8-74.3%) initiated ART prior to delivery; median (IQR) ART duration pre-delivery was 9.5 weeks (5.1-14.2). Among ART-eligible patients, 40.5% (32.3-49.0%) were cumulatively retained through 6 months on ART. Of those ART-ineligible patients at HIV testing, only 22.6% (95% CI 15.9-30.6%) completed CD4 staging and returned for a repeat CD4 test after delivery. LTFU (≥1 month late for last scheduled visit) before delivery was 20.5% (95% CI 16.0-25.6%) and, among those still in care, 47.9% (95% CI 41.2-54.6%) within 6 months after delivery. Overall, 57.5% (95% CI 51.6-63.3%) were lost between HIV testing and 6 months post-delivery. CONCLUSIONS: Our findings highlight the challenge of continuity of care among HIV-positive pregnant women attending antenatal services, particularly those ineligible for ART.
Authors: Lytt I Gardner; Lisa R Metsch; Pamela Anderson-Mahoney; Anita M Loughlin; Carlos del Rio; Steffanie Strathdee; Stephanie L Sansom; Harvey A Siegal; Alan E Greenberg; Scott D Holmberg Journal: AIDS Date: 2005-03-04 Impact factor: 4.177
Authors: Jason A Craw; Lytt I Gardner; Gary Marks; Richard C Rapp; Jeff Bosshart; Wayne A Duffus; Amber Rossman; Susan L Coughlin; DeAnn Gruber; Lauretta A Safford; Jon Overton; Karla Schmitt Journal: J Acquir Immune Defic Syndr Date: 2008-04-15 Impact factor: 3.731
Authors: Jeannette R Ickovics; Tracey E Wilson; Rachel A Royce; Howard L Minkoff; M Isabel Fernandez; Rachel Fox-Tierney; Linda J Koenig Journal: J Acquir Immune Defic Syndr Date: 2002-07-01 Impact factor: 3.731
Authors: C A Mellins; C Chu; K Malee; S Allison; R Smith; L Harris; A Higgins; C Zorrilla; S Landesman; L Serchuck; P Larussa Journal: AIDS Care Date: 2008-09
Authors: James T Pfeiffer; Manuel Napúa; Bradley H Wagenaar; Falume Chale; Roxanne Hoek; Mark Micek; João Manuel; Cathy Michel; Jessica Greenberg Cowan; James F Cowan; Sarah Gimbel; Kenneth Sherr; Stephen Gloyd; Rachel R Chapman Journal: J Acquir Immune Defic Syndr Date: 2017-11-01 Impact factor: 3.731
Authors: Katherine B Rucinski; Sheree R Schwartz; Kimberly A Powers; Brian W Pence; Benjamin H Chi; Vivian Black; Helen Rees; Audrey E Pettifor Journal: AIDS Behav Date: 2020-06
Authors: Christina Psaros; Jocelyn E Remmert; David R Bangsberg; Steven A Safren; Jennifer A Smit Journal: Curr HIV/AIDS Rep Date: 2015-03 Impact factor: 5.071
Authors: Hae-Young Kim; David W Dowdy; Neil A Martinson; Deanna Kerrigan; Carrie Tudor; Jonathan Golub; John F P Bridges; Colleen F Hanrahan Journal: AIDS Behav Date: 2019-07
Authors: Mary Jane Rotheram-Borus; Thomas W Weichle; Adriane Wynn; Ellen Almirol; Emily Davis; Jacqueline Stewart; Sarah Gordon; Julia Tubert; Mark Tomlinson Journal: AIDS Behav Date: 2019-12
Authors: Kathleen Miller; Winnie Muyindike; Lynn T Matthews; Michael Kanyesigye; Mark J Siedner Journal: AIDS Patient Care STDS Date: 2017-06-26 Impact factor: 5.078
Authors: Christopher J Hoffmann; Silvia Cohn; Fildah Mashabela; Jennifer D Hoffmann; Helen McIlleron; Paolo Denti; David W Haas; Kelly E Dooley; Neil A Martinson; Richard E Chaisson Journal: J Acquir Immune Defic Syndr Date: 2016-01-01 Impact factor: 3.731